A ROUTE TO

BIOSIMILARS

Follow the paths below to see key points in the biosimilar adoption process.

Based on the experience at a major health care institution. The adoption process and roles may vary by institution.

Based on the experience at a major health care institution. The adoption process and roles may vary by institution.

 
 
 

DECIDING TO ADOPT A BIOSIMILAR

Building knowledge

  • Evaluating the clinical and financial implications of pursuing a biosimilar switch, including obtaining input from physicians, the supply chain, and other stakeholders
  • Investigating the clinical evidence
    • Examining the available information/data
    • Reviewing the Prescribing Information
  • Assessing the possibility of long-term savings to the organization, specifically for pharmacy directors, procurement and supply chain specialists, and finance directors

WHO MAY BE INVOLVED AT THIS STEP:

Physicians

Physicians

Supply Chain

Supply Chain

Pharmacy Director or Change Leader

Pharmacy Director or Change Leader

Finance Director

Finance Director

Pharmacy and Therapeutics Committee

Pharmacy and Therapeutics Committee

Department Chairs

Department Chairs

Who may be involved at this step?

Assessing the payer landscape

  • Getting an initial understanding of the payer landscape

WHO MAY BE INVOLVED AT THIS STEP:

Coverage & Reimbursement

Coverage & Reimbursement

Pharmacy Director or Change Leader

Pharmacy Director or Change Leader

Finance Director

Finance Director

Supply Chain

Supply Chain

Health Care Professionals

Health Care Professionals

Who may be involved at this step?

Building a consensus

  • Presenting recommendations to the pharmacy and therapeutics (P&T) committee for its buy-in
  • Obtaining endorsements from department chairs

WHO MAY BE INVOLVED AT THIS STEP:

Pharmacy and Therapeutics Committee

Pharmacy and Therapeutics Committee

Department Chairs

Department Chairs

Who may be involved at this step?

 
Back to top

IMPLEMENTING A BIOSIMILAR

Updating systems

  • Optimizing the electronic health record (EHR) system
  • Streamlining order sets and protocols

WHO MAY BE INVOLVED AT THIS STEP:

Pharmacy Director or Change Leader

Pharmacy Director or Change Leader

Pharmacy and Therapeutics Committee

Pharmacy and Therapeutics Committee

Department Chairs

Department Chairs

Who may be involved at this step?

Addressing the payer landscape and reimbursement

  • Identifying appropriate patients
  • Reviewing billing requirements
  • Assessing the payer formulary
  • Evaluating payer utilization management criteria
  • Researching patient support programs

WHO MAY BE INVOLVED AT THIS STEP:

Coverage & Reimbursement

Coverage & Reimbursement

Pharmacy Director or Change Leader

Pharmacy Director or Change Leader

Finance Director

Finance Director

Supply Chain

Supply Chain

Health Care Professionals

Health Care Professionals

Who may be involved at this step?

Educating and communicating key information

  • Determining the implementation date
  • Outlining possible changes to the EHR system
  • Addressing insurance information
  • Communicating to patients that they are being switched to a biosimilar that has shown no clinically meaningful differences in terms of safety, purity, and potency

WHO MAY BE INVOLVED AT THIS STEP:

Health Care Professionals

Health Care Professionals

Patients

Patients

Pharmacists

Pharmacists

Who may be involved at this step?

Going live

  • Supporting patients through patient access programs
  • Providing physicians, nurses, pharmacists, and patients with a resource that includes consistent contact information for questions

WHO MAY BE INVOLVED AT THIS STEP:

Coverage & Reimbursement

Coverage & Reimbursement

Patients

Patients

Health Care Professionals

Health Care Professionals

Pharmacists

Pharmacists

Who may be involved at this step?

 
Back to top

MONITORING BIOSIMILAR USE AND EXPERIENCE

 

Measuring and proving success

  • Regularly reporting (eg, quarterly) to department chairs, the hospital administration, and the organization’s pharmacy and therapeutics committee

WHO MAY BE INVOLVED AT THIS STEP:

Pharmacy Director or Change Leader

Pharmacy Director or Change Leader

Pharmacy and Therapeutics Committee

Pharmacy and Therapeutics Committee

Department Chairs

Department Chairs

Who may be involved at this step?

Back to top